Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 Synthase

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2025-02-17 DOI:10.1021/acs.jmedchem.4c02897

Gebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, David Orain, Carsten Spanka, Odile Decoret, Romain M. Wolf, Brian Hurley, Atwood K. Cheung, David A. Sandham, Ayako Honda, Ritesh Tichkule, Xin Chen, Tajesh Patel, Nancy Labbe-Giguere, Kian L. Tan, Clayton Springer, John Manchester, Andrew J. Culshaw, Peter Hunt, Honnappa Srinivas, Carlos A. Penno, Sandrine Ferrand, Shin Numao, Ulrich Schopfer, Petra Jäger, Nathalie Wack, Franziska Hasler, Beatrice Urban, Miriam Sindelar, Pius Loetscher, Michael Kiffe, Xiaojun Ren, Paul Nicklin, Kevin White, Khaushik Subramanian, Haoyuan Liu, Ellena J. Growcott, Till A. Röhn

{"title":"Discovery of GJG057, a Potent and Highly Selective Inhibitor of Leukotriene C4 Synthase","authors":"Gebhard Thoma, Wolfgang Miltz, Rudolf Waelchli, David Orain, Carsten Spanka, Odile Decoret, Romain M. Wolf, Brian Hurley, Atwood K. Cheung, David A. Sandham, Ayako Honda, Ritesh Tichkule, Xin Chen, Tajesh Patel, Nancy Labbe-Giguere, Kian L. Tan, Clayton Springer, John Manchester, Andrew J. Culshaw, Peter Hunt, Honnappa Srinivas, Carlos A. Penno, Sandrine Ferrand, Shin Numao, Ulrich Schopfer, Petra Jäger, Nathalie Wack, Franziska Hasler, Beatrice Urban, Miriam Sindelar, Pius Loetscher, Michael Kiffe, Xiaojun Ren, Paul Nicklin, Kevin White, Khaushik Subramanian, Haoyuan Liu, Ellena J. Growcott, Till A. Röhn","doi":"10.1021/acs.jmedchem.4c02897","DOIUrl":null,"url":null,"abstract":"Leukotriene C4 synthase (LTC4S) is a glutathione S-transferase that mediates the biosynthesis of cysteinyl leukotriene C4 (LTC4). Cysteinyl leukotrienes (CysLTs) are lipid mediators that drive type 2 inflammation, bronchoconstriction, and itch. Thus, LTC4S represents an attractive drug target for the treatment of allergic inflammatory diseases, but to date, no LTC4S inhibitor has been tested in patients. Herein, we disclose the discovery and preclinical profiling of the highly selective, oral LTC4S inhibitor GJG057 (compound 1), which exhibits 20-fold improved potency (IC50 = 44 nM) versus clinical candidate AZD9898 (IC50 = 900 nM) in a human whole blood LTC4 release assay. GJG057 showed efficacy in a murine asthma exacerbation model as well as in a mastoparan-induced skin challenge PK/PD model and was profiled in GLP toxicology studies. Despite its promising properties, GJG057 was not progressed into clinical trials as an oral drug. Its potential as a topical drug is currently being evaluated.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"24 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02897","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Leukotriene C4 synthase (LTC4S) is a glutathione S-transferase that mediates the biosynthesis of cysteinyl leukotriene C4 (LTC4). Cysteinyl leukotrienes (CysLTs) are lipid mediators that drive type 2 inflammation, bronchoconstriction, and itch. Thus, LTC4S represents an attractive drug target for the treatment of allergic inflammatory diseases, but to date, no LTC4S inhibitor has been tested in patients. Herein, we disclose the discovery and preclinical profiling of the highly selective, oral LTC4S inhibitor GJG057 (compound 1), which exhibits 20-fold improved potency (IC₅₀ = 44 nM) versus clinical candidate AZD9898 (IC₅₀ = 900 nM) in a human whole blood LTC4 release assay. GJG057 showed efficacy in a murine asthma exacerbation model as well as in a mastoparan-induced skin challenge PK/PD model and was profiled in GLP toxicology studies. Despite its promising properties, GJG057 was not progressed into clinical trials as an oral drug. Its potential as a topical drug is currently being evaluated.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.